You just read:

BerGenBio to Present Interim Phase 2 Clinical Data With Selective AXL Inhibitor Bemcentinib in Non-small Cell Lung Cancer at WCLC

News provided by

BerGenBio ASA

05 Sep, 2018, 08:18 BST